
News|Videos|March 5, 2025
Patient Selection and Billing Considerations for Swift Wart Treatment
Author(s)Sponsored by Swift
Dustin Portela, DO, discusses patient selection and affordability considerations for Swift microwave therapy. He explores how the treatment process works and strategies to ensure patient comfort during sessions.
Advertisement
Episodes in this series

Advertisement
Related to this article

FDA implements updated iPLEDGE REMS requirements for isotretinoin, allowing at-home pregnancy testing and reducing prescription and counseling burdens.

Bosakitug failed to meet primary and secondary endpoints in a phase 2 atopic dermatitis trial despite evidence of TSLP target engagement.

Recent dermatology research explores chronic hand eczema prevalence, cancer risk in morphea, pernio, biologic optimization in HS, and melanoma risk prediction.

Hypochlorous acid sprays are trending as a post-gym skin care essential, but can they actually prevent sweat-related breakouts?

Clinicians discuss how type 2 inflammation informs treatment decisions across AD, prurigo nodularis, CSU, and bullous pemphigoid.

A pediatric dermatologist explains how CALM count, size, age, and associated findings separate benign spots from neurofibromatosis type 1 and its mimics.

At a Dermatology Times Case-Based Roundtable, Vishal A. Patel, MD, led a discussion on treatment selection, tolerability, and individualized care for patients with advanced basal cell carcinoma.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Implements Updated iPLEDGE REMS Requirements for Isotretinoin
2
Aclaris' Bosakitug Misses Phase 2 Endpoints in Atopic Dermatitis
3
Phase 3 Trial Supports Risankizumab for Pediatric Psoriasis
4
Social Media Mythbusters: Do Post-Workout Sprays Prevent Acne?
5

